Working… Menu

An Open-labeled Phase II Study to Evaluate the Efficacy and Safety of GXNPC-1 in Patients With Chronic Stroke

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04088149
Recruitment Status : Recruiting
First Posted : September 12, 2019
Last Update Posted : February 13, 2020
Information provided by (Responsible Party):
Gwo Xi Stem Cell Applied Technology Co., Ltd.

Brief Summary:
The primary objective of this study is to evaluate the efficacy for subjects with chronic stroke after GXNPC-1 injection.

Condition or disease Intervention/treatment Phase
Chronic Stroke Drug: GXNPC1 Phase 2

Detailed Description:
This is an open-label, single center, sequentially study in subjects with chronic stroke. Considering 20% dropout rate (based on evaluable versus treated patients), approximately 15 subjects will be enrolled, and at least 12 subjects will be evaluable. Cohort 1 will recruit the first 3 evaluable subjects assigned to receive low dose of GXNPC-1. The following 3 evaluable subjects will be enrolled sequentially and treated with high dose of GXNPC-1 in cohort 2. In cohort 3, another 6 evaluable subjects will be enrolled to take high dose of GXNPC-1. There will be 2 parts of this study including GXNPC-1 preparation and GXNPC-1 treatment in chronic stroke subjects, respectively.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: GXNPC1 Injections for Chronic Stroke
Actual Study Start Date : February 6, 2020
Estimated Primary Completion Date : October 31, 2021
Estimated Study Completion Date : October 31, 2021

Arm Intervention/treatment
Experimental: GXNPC1

There are 2 dose levels Cohort 1: Low dose (1 ± 0.1 × 10^8 GXNPC1) of IPs will be administered in parallel.

Cohort 2: High dose (2 ± 0.2 × 10^8 GXNPC1) of IPs will be administered sequentially.

Drug: GXNPC1
Autologous ADSCs
Other Name: hADSCs

Primary Outcome Measures :
  1. NIHSS [ Time Frame: 1-6 month ]
    The net change on NIHSS at each evaluation time point

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years to 85 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female who are aged between 65 and 85 years old on date of consent
  2. Post-stroke between 6 months and 15 years at the screening
  3. Subjects who have had stroke(s) in carotid artery distribution area, and the location of ischemic stroke should be diagnosed by magnetic resonance image (MRI)
  4. Subjects who have had the brain injured area with diameter between 0.5 and 10 cm according to MRI evaluation
  5. Subjects who have National Institutes of Health Stroke Scale (NIHSS) score between 8 and 30 at the screening
  6. Subjects who had stroke with hemiparesis (remaining residual limb movement, defined as score less than 4 on questions 5 or 6 on the NIHSS for the affected limbs) at screening.
  7. Subjects who have stable NIHSS (±3) for at least 2 weeks from Visit 1 (screening) to Visit2 (prior to operation)
  8. Subjects with systolic blood pressure less than 200 mmHg (an average based on ≥2 readings) at screening, prior to the operation for fat tissue acquisition (Visit 2), and before the surgery for ADSC administration (Visit 3)
  9. Subjects with International normalized ration (INR) < 2.5, and platelet between 1 × 105/μL and 5 × 105/μL at the screening
  10. Female subjects with childbearing potential should be confirmed of not being pregnant or lactating at the screening and during the study.
  11. All male subjects and female subjects with child-bearing potential (between puberty and 2 years after menopause) should use reliable contraception method(s), such as tubal ligation, vasectomy, intrauterine device (IUD), intrauterine system (IUS), hormonal contraception or condom, during this study when they have sexual behavior.
  12. Neurology physician judges the recent symptoms in subjects are correlated to the stroke area.
  13. Subjects or the legally acceptable representative are willing to sign informed consent form (ICF).

Exclusion Criteria:

  1. Subjects who are suffered by clinically significantly autoimmune conditions, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS) or psoriasis
  2. Subjects who are unable to undergo MRI and Computed tomography (CT) scans for any reason
  3. Subjects who have multiple stenosis in intracranial blood vessels
  4. Subjects receiving antiplatelets (e.g., aspirin and persantin) and/or anticoagulants (e.g., warfarin) cannot temporarily cease the treatment within 3 days before fat tissue acquisition (Visit 2) or ADSCs administration (Visit 3).
  5. Subjects who receive systemic immunosuppressive treatments, immunotherapy, or cytotoxic drug within 1 month before screening
  6. Subjects with inadequate hepatic function at the screening visit: Alanine aminotransaminase (ALT), Aspartate aminotransaminase (AST), and alkaline phosphatase (ALP) ≥ 2X upper limit of normal (ULN).
  7. Subjects with inadequate renal function at the screening visit: Blood urea nitrogen (BUN) ≥ 30 mg/dl; serum creatinine ≥ 3 mg/dl
  8. Subjects who have medical historical or clinically active spinal injury, Alzheimer's disease, Parkinson's disease, spinocerebellar ataxia (SCA), spinal muscular atophy (SMA) or other clinically significant neurological diseases that will confound the evaluation of this study
  9. Subjects who have clinically severe and/or life-threatening disease(s) such as uncontrolled diabetes or malignant tumor
  10. Subjects who have risk for the following infectious diseases: human immunodeficiency virus (HIV), syphilis, or human transmissible spongiform encephalopathy (TSE), such as Creutzfeldt-Jakob disease (CJD)
  11. Subject who fails to generate adequate amount of ADSCs before administration at Visit 3
  12. Female subject who is lactating, pregnant, or planned to be pregnant
  13. Subject with known or suspected hypersensitivity to GXNPC-1 or its excipients
  14. Subject with any complication by chest X-ray and electrocardiogram (ECG) evaluation
  15. Subjects who have participated in other investigational studies and received any treatment within 4 weeks prior to screening
  16. Subjects not suitable to participate the trial as judged by the investigator(s)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04088149

Layout table for location contacts
Contact: Huang Sabrina +886-3-6585959 ext 332

Layout table for location information
HualienTzu Chi Hospital Recruiting
Hualien City, Taiwan, 700
Sponsors and Collaborators
Gwo Xi Stem Cell Applied Technology Co., Ltd.
Layout table for investigator information
Principal Investigator: CHIU T LANG, Director Hualien Tzu Chi General Hospital
Layout table for additonal information
Responsible Party: Gwo Xi Stem Cell Applied Technology Co., Ltd. Identifier: NCT04088149    
Other Study ID Numbers: GXNPC1
First Posted: September 12, 2019    Key Record Dates
Last Update Posted: February 13, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases